Page last updated: 2024-12-08

5-diphosphomevalonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-diphosphomevalonic acid: RN given refers to ion(1-) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(R)-5-diphosphomevalonic acid : The 5-diphospho derivative of (R)-mevalonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439418
CHEMBL ID235881
CHEBI ID15899
SCHEMBL ID3272270
MeSH IDM0134190

Synonyms (29)

Synonym
gtpl3047
(3r)-3-hydroxy-5-(hydroxy-phosphonooxyphosphoryl)oxy-3-methylpentanoic acid
(r)-5-diphosphomevalonic acid
CHEBI:15899 ,
(3r)-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentanoic acid
(3r)-3-hydroxy-5-{[(r)-hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentanoic acid
DP6 ,
C01143 ,
diphosphomelavonate
CHEMBL235881
mevelonate-5-diphosphate
(3r)-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
5-diphosphomevalonic acid
3r-methyl-3-hydroxypentanoic acid 5-diphosphate
LMFA01050416
(r)-mevalonic acid 5-diphosphate
mevalonate-pp
mevalonate-5pp
mevalonate pyrophosphate
SCHEMBL3272270
mevalonic acid, r, pyrophosphate
103025-21-4
1,1,3,7-tetrahydroxy-7-methyl-2,4-dioxa-1,3-diphosphanonan-9-oic acid ion(1-)1,3-dioxide
mevalonate-diphosphate
5-diphosphomevalonate
(3r)-3-hydroxy-5-((hydroxy(phosphonooxy)phosphoryl)oxy)-3-methylpentanoic acid
Q27088509
mevalonic acid,r,pyrophosphate
DTXSID401344788
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carboxyalkyl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (47)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Metabolism of proteins1058144
Terpenoid Backbone Biosynthesis1322
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
Synthesis of Dolichyl-phosphate617
Steroids metabolism ( Steroids metabolism )1627
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Cholesterol Biosynthesis and Metabolism2248
Mevalonate pathway010
Ergosterol biosynthesis332
superpathway of sterol biosynthesis050
Biochemical pathways: part I0466
MVA pathway116

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID301996Activity of MDD K27A mutant2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase.
AID301997Activity of MDD R154A mutant2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase.
AID301995Activity of wild type MDD in rat liver2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase.
AID456899Binding affinity to Streptococcus pneumoniae mevalonate kinase2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae.
AID1346897Human phosphomevalonate kinase (Lanosterol biosynthesis pathway)2007Biochemistry, Oct-23, Volume: 46, Issue:42
Functional evaluation of conserved basic residues in human phosphomevalonate kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (20.69)18.7374
1990's4 (13.79)18.2507
2000's8 (27.59)29.6817
2010's10 (34.48)24.3611
2020's1 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]